Regeneron Reports observational study Data for Emicizumab in Prostate cancer

Regeneron today announced observational study results for Emicizumab in patients with Prostate cancer. The study demonstrated that Emicizumab demonstrates favorable safety profile compared to standard of care or placebo. These results provide important insights into the treatment of Prostate cancer and support the continued development of Emicizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Emicizumab was consistent with previous observations, with no new safety signals identified.